Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune, Transplantation, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD83 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD83 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View CD83 Products |
| Gene Delivery | CD83 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and surface expression validation. |
View CD83 Products |
| Benchmark Ab | Anti-CD83 (Sequence of 3C12 / Clinical Candidate) Recombinant positive control antibody for assay calibration. |
View CD83 Products |
| Validator | CD83 siRNA Set For target knockdown verification and specificity profiling. |
View CD83 Products |
| Related Target A | CD80 Co-stimulatory molecule critical for dendritic cell-mediated T-cell activation pathways. |
View CD80 Products |
| Related Target B | CD86 In tandem with CD80/CD83, mediates critical checkpoint signals in autoimmune pathology. |
View CD86 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing Membrane CD83 from Soluble CD83 (sCD83) | HEK293 expressed recombinant ECD-Fc proteins preserve native glycosylation and conformational epitopes. |
| Cross-Species Reactivity Profiling (Cyno/Mouse) | Human, Mouse, and Cynomolgus CD83 ortholog proteins available with strictly verified sequence identity. |
| Lack of Controls in Depletion Assays | Recombinant clinical benchmark antibodies (biosimilars) included for assay standardization. |
| Off-Target Binding & False Positives | High-purity monomers and sequence-verified siRNA sets ensure strict specificity validation. |
Live CD83 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of CD83 is undergoing a significant transition. Historically recognized as a marker for mature dendritic cells (DCs), CD83 has emerged as a pivotal immune regulator in graft-versus-host disease (GvHD), transplant rejection, and autoimmune disorders. The race for CD83 therapeutics is intensifying, with major players shifting focus from traditional systemic immunosuppression to targeted depletion of activated CD83+ cells and the therapeutic application of soluble CD83 (sCD83) fusion proteins. As first-generation therapies reach clinical evaluations, the next wave of R&D is targeting highly specific monoclonal antibodies, ADCs, and CAR-T therapies to selectively eliminate alloreactive immune cells while sparing regulatory populations.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Depleting) | Biotech & Academic Consortia | Graft-Versus-Host Disease (GvHD), Transplant Rejection | ADCC/CDC assays (Requires native-conformation CD83 expressing target cell lines via Lentivirus) |
| Soluble CD83 Fusion Protein | Immunology Specialists | Rheumatoid Arthritis, Multiple Sclerosis, Inflammatory Bowel Disease | Ligand binding and receptor identification (Requires high-purity, endotoxin-controlled CD83 ECD-Fc) |
| CAR-T Therapy | Oncology & Autoimmune Innovators | Hematological Malignancies, Severe Autoimmune Disease | CAR expression and binding affinity screening (Requires sequence-verified monomeric CD83 antigens) |